Nurix Therapeutics
Quarterly Financials
| Values in thousands | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|---|
Revenue | $6,252 | $13,577 | $7,894 | $44,056 |
Gross Profit | -77,885 | 8,946 | 2,894 | -34,040 |
EBITDA | -92,495 | -68,957 | -81,421 | -46,080 |
EBIT | -78,221 | -86,421 | -48,322 | |
Net Income | -87,174 | -78,221 | -86,421 | -43,464 |
Net Change In Cash | 6,252 | 13,577 | 7,894 | 44,056 |
Free Cash Flow | -72,959 | -72,963 | -60,096 | -65,836 |
Cash | 71,195 | 246,960 | 78,438 | 84,260 |
Basic Shares | 110,071 | 95,089 | 84,159 | 83,882 |
Annual Financials
| Values in thousands | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
Revenue | $83,980 | $54,549 | $76,987 | $38,627 |
Gross Profit | 65,123 | -167,083 | -112,161 | 38,627 |
EBITDA | -244,841 | -205,009 | -148,930 | -173,059 |
EBIT | -263,697 | -213,027 | -155,063 | -183,867 |
Net Income | -264,457 | -193,569 | -143,948 | -166,045 |
Net Change In Cash | 83,980 | 54,549 | 76,987 | 38,627 |
Cost of Revenue | -15,417 | |||
Free Cash Flow | -263,467 | -181,857 | -89,766 | -172,051 |
Cash | 246,960 | 109,997 | 54,627 | 64,474 |
Basic Shares | 86,666 | 67,120 | 54,337 | 48,607 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-02-28 | -$0.79 |
2025-11-30 | -$0.82 |
2025-08-31 | -$1.03 |
2025-05-31 | -$0.52 |